MIAMI, FL – – Addressing a critical infrastructure gap in Latin American healthcare, radiopharmaceutical pioneers Nucleotron MIT (a CIRA Health company) and clinical research experts bioaccess® today announced the formation of SYNAPSE GLOBAL THERANOSTICS INC., a new joint venture operating as Synapse Latam. The new company will operate as a global Management Services Organization (MSO), deploying a proven U.S. operational model to establish a network of world-class molecular imaging and theranostics centers across the region.
Synapse Latam is poised to transform the landscape of precision medicine for millions of patients by solving the chronic scarcity of essential radiopharmaceuticals—the radioactive drugs required for advanced diagnostic imaging (like PET scans) and targeted cancer therapies. While many Latin American hospitals have invested in state-of-the-art imaging scanners, a fragile global supply chain and lack of local production capabilities have left this equipment underutilized, delaying patient diagnoses and limiting access to cutting-edge clinical trials.
Through knowledge transfer agreements, the new venture will provide healthcare partners with a complete, end-to-end ecosystem of services, including theranostic program development, clinical research administration, and radiopharmaceutical strategy. This model is a direct transfer of the successful operational blueprint established by CIRA Health, a U.S. leader in molecular imaging and theranostics research.
"Synapse Latam is not just a company; it's a solution to one of the most significant barriers facing modern medicine in Latin America," said Julio Martinez-Clark, CEO of bioaccess®. "For years, the region's potential to participate in global clinical trials has been hampered by infrastructure challenges. By combining our deep regulatory and clinical trial expertise with Nucleotron's unparalleled technical know-how, we are creating a powerful platform to accelerate research, attract investment, and, most importantly, provide patients with early access to the next generation of life-saving therapies."
A cornerstone of the Synapse Latam offering is its exclusive regional right to provide the IONETIX ION-12SC, a revolutionary, FDA-cleared superconducting cyclotron. Its compact design and lower operational costs make on-site, on-demand production of radiopharmaceuticals feasible for hospitals, eliminating reliance on unstable import channels and turning a prohibitive cost center into a hub for clinical and economic leadership.
The joint venture launches with an established client, demonstrating immediate market traction and a clear path for expansion. Initial project include turnkey cyclotron and radiopharmacy implementations at leading institutions such as the Hospital Internacional de Colombia (HIC),
"We are replicating a model that has proven incredibly successful in the United States, centered on clinical enablement, operational excellence, and technological superiority," said a representative for Nucleotron MIT. "Our partnership with bioaccess® creates a single, accountable entity that can de-risk the entire process for our partners—from initial financial modeling and facility design to regulatory approval and integration into global clinical trial networks. Our vision is to build a resilient, collaborative grid of theranostics centers that will establish Latin America as a global leader in precision medicine."
By leveraging bioaccess®'s expertise in navigating the region's regulatory agencies, Synapse Latam projects it can accelerate the launch of new facilities by up to 40% compared to traditional pathways, bringing critical new treatments to patients faster than ever before.
About SYNAPSE GLOBAL THERANOSTICS INC. (Synapse Latam)Synapse Latam is a Management Services Organization (MSO) created to build and expand advanced theranostics and clinical research capabilities across Latin America. A 50/50 joint venture between Nucleotron MIT and bioaccess®, the company provides a comprehensive, turnkey solution for hospitals and research centers, deploying a proven U.S. operational model to establish regional leadership in precision medicine.
About Nucleotron MIT and CIRA Health: Nucleotron MIT, a company of U.S. molecular imaging leader CIRA Health, is a team of radiopharmaceutical pioneers specializing in the design, implementation, and operation of advanced molecular imaging infrastructure. The company provides turnkey solutions for cGMP-compliant radiopharmacies and holds exclusive rights to the IONETIX ION-12SC cyclotron technology for Latin America.
About bioaccess®bioaccess® is a global contract research organization (CRO) that empowers medical technology companies to accelerate early-feasibility and first-in-human clinical trials. With deep expertise in Latin America, the company specializes in market access, regulatory strategy, and clinical trial management, offering a fast-track pathway for innovators to bring next-generation medical treatments to patients.